-
1
-
-
84871138371
-
-
Česká onkologická společnost ČLS JEP, Česká republika. 11. vydání [aktualizováno 1. srpna 2010; citováno 4. října 2010]. Dostupné z
-
Zásady cytostatické léčby maligních onkologických onemocnění. Česká onkologická společnost ČLS JEP, Česká republika. 11. vydání [aktualizováno 1. srpna 2010; citováno 4. října 2010]. Dostupné z: http://wwwlinkos.cz/odbornici/info-praxe/standardyphp?t=1.
-
Zásady Cytostatické Léčby Maligních Onkologických Onemocnění
-
-
-
2
-
-
0142055937
-
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
-
DOI 10.1001/jama.290.16.2149
-
Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 2003; 290(16): 2149-2158. (Pubitemid 37432975)
-
(2003)
Journal of the American Medical Association
, vol.290
, Issue.16
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
Lynch Jr., T.J.4
Prager, D.5
Belani, C.P.6
Schiller, J.H.7
Kelly, K.8
Spiridonidis, H.9
Sandler, A.10
Albain, K.S.11
Cella, D.12
Wolf, M.K.13
Averbuch, S.D.14
Ochs, J.J.15
Kay, A.C.16
-
3
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
-
DOI 10.1200/JCO.2003.10.038
-
Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21(12): 2237-2246. (Pubitemid 46621858)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.12
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
Tamura, T.4
Nakagawa, K.5
Douillard, J.-Y.6
Nishiwaki, Y.7
Vansteenkiste, J.8
Kudoh, S.9
Rischin, D.10
Eek, R.11
Horai, T.12
Noda, K.13
Takata, I.14
Smit, E.15
Averbuch, S.16
Macleod, A.17
Feyereislova, A.18
Dong, R.-P.19
Baselga, J.20
more..
-
4
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
DOI 10.1016/S0140-6736(05)67625-8, PII S0140673605676258
-
Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366(9496): 1527-1537. (Pubitemid 41540110)
-
(2005)
Lancet
, vol.366
, Issue.9496
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
Pereira, J.R.4
Ciuleanu, T.5
Von Pawel, J.6
Thongprasert, S.7
Tan, E.H.8
Pemberton, K.9
Archer, V.10
Carroll, K.11
-
5
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
DOI 10.1056/NEJMoa050753
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-132. (Pubitemid 41058344)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.2
, pp. 123-132
-
-
Shepherd, F.A.1
Pereira, J.R.2
Ciuleanu, T.3
Eng, H.T.4
Hirsh, V.5
Thongprasert, S.6
Campos, D.7
Maoleekoonpiroj, S.8
Smylie, M.9
Martins, R.10
Van Kooten, M.11
Dediu, M.12
Findlay, B.13
Tu, D.14
Johnston, D.15
Bezjak, A.16
Clark, G.17
Santabarbara, P.18
Seymour, L.19
-
6
-
-
34247863888
-
The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: A prospective study
-
PII 0124389420061100000008
-
Lee DH, Han JY, Yu SY et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol 2006; 1(9): 965-971. (Pubitemid 47181364)
-
(2006)
Journal of Thoracic Oncology
, vol.1
, Issue.9
, pp. 965-971
-
-
Lee, D.H.1
Han, J.-Y.2
Yu, S.Y.3
Kim, H.Y.4
Nam, B.-H.5
Hong, E.K.6
Kim, H.T.7
Lee, J.S.8
-
7
-
-
79955558470
-
Cílená léřba nemalobuněč ného karcinomu plic (NSCLC)
-
[aktualizováno 28. března 2010; citováno 4. října 2010]. Dostupné z
-
Zatloukal P. Cílená léřba nemalobuněčného karcinomu plic (NSCLC). Medical Tribune 2010; 6 [aktualizováno 28. března 2010; citováno 4. října 2010]. Dostupné z: http://wwwtribune.cz/clanek/17123.
-
(2010)
Medical Tribune
, pp. 6
-
-
Zatloukal, P.1
-
8
-
-
79955562352
-
Mutace genů EGFR1 a KRAS
-
V dny diagnostické, prediktivní a experimentá lní onkologie & II. sympózium o cílené biologické léčbě, 25.-27. 11. 2009, Olomouc
-
Hajdúch M. Mutace genů EGFR1 a KRAS. In: V dny diagnostické, prediktivní a experimentální onkologie & II. sympózium o cílené biologické léčbě, 25.-27. 11. 2009, Olomouc. Onkologie 2009; 3 (Suppl B): 11-12.
-
(2009)
Onkologie
, vol.3
, Issue.SUPPL. B
, pp. 11-12
-
-
Hajdúch, M.1
-
9
-
-
77956071233
-
Cílená léčba bronchioloalveolá rního plicního adenokarcinomu inhibitory tyrozinkiná zové aktivity EGFR: Kazuistika klinicky promptní a výrazné odpovědi a přehled literatury
-
Svoboda M, Fabian P, Slabý O et al. Cílená léčba bronchioloalveolárního plicního adenokarcinomu inhibitory tyrozinkinázové aktivity EGFR: kazuistika klinicky promptní a výrazné odpovědi a přehled literatury Klin Onkol 2010, 23(4): 224-230.
-
(2010)
Klin Onkol
, vol.23
, Issue.4
, pp. 224-230
-
-
Svoboda, M.1
Fabian, P.2
Slabý, O.3
-
10
-
-
2342471392
-
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
-
DOI 10.1056/NEJMoa040938
-
Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-2139. (Pubitemid 38637993)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.21
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
11
-
-
2342624080
-
EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy
-
DOI 10.1126/science.1099314
-
Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676): 1497-1500. (Pubitemid 38720929)
-
(2004)
Science
, vol.304
, Issue.5676
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
12
-
-
33750205340
-
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
-
DOI 10.1038/sj.bjc.6603393, PII 6603393
-
Asahina H, Yamazaki K, Kinoshita I et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006; 95(8): 998-1004 (Pubitemid 44606825)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.8
, pp. 998-1004
-
-
Asahina, H.1
Yamazaki, K.2
Kinoshita, I.3
Sukoh, N.4
Harada, M.5
Yokouchi, H.6
Ishida, T.7
Ogura, S.8
Kojima, T.9
Okamoto, Y.10
Fujita, Y.11
Dosaka-Akita, H.12
Isobe, H.13
Nishimura, M.14
-
13
-
-
33845262077
-
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
-
DOI 10.1038/sj.bjc.6603466, PII 6603466
-
Sutani A, Nagai Y, Udagawa K et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp Br J Cancer 2006; 95(11): 1483-1489. (Pubitemid 44863350)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.11
, pp. 1483-1489
-
-
Sutani, A.1
Nagai, Y.2
Udagawa, K.3
Uchida, Y.4
Koyama, N.5
Murayama, Y.6
Tanaka, T.7
Miyazawa, H.8
Nagata, M.9
Kanazawa, M.10
Hagiwara, K.11
Kobayashi, K.12
-
14
-
-
33746789922
-
Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
-
DOI 10.1200/JCO.2005.05.4692
-
Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24(21): 3340-3346. (Pubitemid 46638887)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.21
, pp. 3340-3346
-
-
Inoue, A.1
Suzuki, T.2
Fukuhara, T.3
Maemondo, M.4
Kimura, Y.5
Morikawa, N.6
Watanabe, H.7
Saijo, Y.8
Nukiwa, T.9
-
15
-
-
34247619676
-
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy
-
DOI 10.1016/j.lungcan.2007.01.025, PII S0169500207000785
-
Sunaga N, Tomizawa Y, Yanagitani N et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy Lung Cancer 2007; 56(3): 383-389. (Pubitemid 46679091)
-
(2007)
Lung Cancer
, vol.56
, Issue.3
, pp. 383-389
-
-
Sunaga, N.1
Tomizawa, Y.2
Yanagitani, N.3
Iijima, H.4
Kaira, K.5
Shimizu, K.6
Tanaka, S.7
Suga, T.8
Hisada, T.9
Ishizuka, T.10
Saito, R.11
Dobashi, K.12
Mori, M.13
-
16
-
-
33845434121
-
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
-
ASCO Meeting Abstract 20. 6. 2006
-
Paz-Ares L, Sanchez JM, Garcia-Velasco A et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). ASCO Meeting Abstract 20. 6. 2006. J Clin Oncol 2006; 24 (Suppl 18): 7020.
-
(2006)
J Clin Oncol
, vol.24
, Issue.SUPPL. 18
, pp. 7020
-
-
Paz-Ares, L.1
Sanchez, J.M.2
Garcia-Velasco, A.3
-
17
-
-
33644982287
-
Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy [1]
-
DOI 10.1200/JCO.2005.04.4420
-
Shepherd FA, Tsao MS. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006; 24(7): 1219-1220. (Pubitemid 46638822)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.7
, pp. 1219-1220
-
-
Shepherd, F.A.1
Tsao, M.-S.2
-
18
-
-
15744372810
-
KRAS mutations and primary resistance of lung adenocarcinoma to gefitinib or erlotinib
-
Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinoma to gefitinib or erlotinib. PLoS Med 2005; 2(1): e17.
-
(2005)
PLoS Med
, vol.2
, Issue.1
-
-
Pao, W.1
Wang, T.Y.2
Riely, G.J.3
-
19
-
-
1542713370
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
-
DOI 10.1200/JCO.2004.07.215
-
Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22(5): 785-794. (Pubitemid 41103589)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.5
, pp. 785-794
-
-
Herbst, R.S.1
Giaccone, G.2
Schiller, J.H.3
Natale, R.B.4
Miller, V.5
Manegold, C.6
Scagliotti, G.7
Rosell, R.8
Oliff, I.9
Reeves, J.A.10
Wolf, M.K.11
Krebs, A.D.12
Averbuch, S.D.13
Ochs, J.S.14
Grous, J.15
Fandi, A.16
Johnson, D.H.17
-
20
-
-
1542503746
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1
-
DOI 10.1200/JCO.2004.08.001
-
Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22(5): 777-784. (Pubitemid 41103588)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.5
, pp. 777-784
-
-
Giaccone, G.1
Herbst, R.S.2
Manegold, C.3
Scagliotti, G.4
Rosell, R.5
Miller, V.6
Natale, R.B.7
Schiller, J.H.8
Von Pawel, J.9
Pluzanska, A.10
Gatzemeier, U.11
Grous, J.12
Ochs, J.S.13
Averbuch, S.D.14
Wolf, M.K.15
Rennie, P.16
Fandi, A.17
Johnson, D.H.18
-
21
-
-
34248140107
-
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
-
Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25(12): 15451-552.
-
(2007)
J Clin Oncol
, vol.25
, Issue.12
, pp. 15451-15552
-
-
Gatzemeier, U.1
Pluzanska, A.2
Szczesna, A.3
-
22
-
-
24944440830
-
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
-
Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23(25): 5892-5899.
-
(2005)
J Clin Oncol
, vol.23
, Issue.25
, pp. 5892-5899
-
-
Herbst, R.S.1
Prager, D.2
Hermann, R.3
-
23
-
-
3442891161
-
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor
-
DOI 10.1158/0008-5472.CAN-04-0562
-
Huang S, Armstrong EA, Benavente S et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64(15): 5355-5362. (Pubitemid 39006556)
-
(2004)
Cancer Research
, vol.64
, Issue.15
, pp. 5355-5362
-
-
Huang, S.1
Armstrong, E.A.2
Benavente, S.3
Chinnaiyan, P.4
Harari, P.M.5
-
24
-
-
64149102776
-
Multi-targeted inhibition of the epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: A phase I study of cetuximab (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors
-
Preston GG, Calvo E, Papadopoulos K et al. Multi-targeted inhibition of the epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: a phase I study of cetuximab (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 3005.
-
ASCO Meeting Abstracts 20. 6. 2006
, vol.24
, Issue.SUPPL. 18
, pp. 3005
-
-
Preston, G.G.1
Calvo, E.2
Papadopoulos, K.3
-
25
-
-
33749237209
-
A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC)
-
Baselga J, Schoffski P, Rojo F et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 3006.
-
ASCO Meeting Abstracts 20. 6. 2006
, vol.24
, Issue.SUPPL. 18
, pp. 3006
-
-
Baselga, J.1
Schoffski, P.2
Rojo, F.3
-
26
-
-
33846688823
-
Total blockade of the epidermal growth factor receptor with the combination of cetuximab and gefitinib: A phase I study for patients with recurrent non-small cell lung cancer (NSCLC)
-
Naret CL, Ramalingam S, Beattie L et al. Total blockade of the epidermal growth factor receptor with the combination of cetuximab and gefitinib: a phase I study for patients with recurrent non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 17045.
-
ASCO Meeting Abstracts 20. 6. 2006
, vol.24
, Issue.SUPPL. 18
, pp. 17045
-
-
Naret, C.L.1
Ramalingam, S.2
Beattie, L.3
-
27
-
-
79955559359
-
Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular targeting agent ZD6126 in human colorectal cancer models
-
Guy SP, Ashton S, Hughes G et al. Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular targeting agent ZD6126 in human colorectal cancer models. Clin Cancer Res 2003; 9: 6143.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 6143
-
-
Guy, S.P.1
Ashton, S.2
Hughes, G.3
-
28
-
-
33750625979
-
A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer
-
Fehrenbacher L, O'Neill V, Belani CP et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 7062.
-
ASCO Meeting Abstracts 20. 6. 2006
, vol.24
, Issue.SUPPL. 18
, pp. 7062
-
-
Fehrenbacher, L.1
O'Neill, V.2
Belani, C.P.3
-
29
-
-
33750087886
-
ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase Il trial
-
Natale RB, Bodkin S, Govindan R et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase Il trial. ASCO Meeting Abstracts 20. 6. 2006; 24 (Suppl 18): 7000.
-
ASCO Meeting Abstracts 20. 6. 2006
, vol.24
, Issue.SUPPL. 18
, pp. 7000
-
-
Natale, R.B.1
Bodkin, S.2
Govindan, R.3
-
30
-
-
33750938418
-
A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results
-
Heymach JV, Johnson BE, Prager DE et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. ASCO Meeting Abstracts 20. 6 2006; 24(Suppl 18): 7016.
-
ASCO Meeting Abstracts 20. 6 2006
, vol.24
, Issue.SUPPL. 18
, pp. 7016
-
-
Heymach, J.V.1
Johnson, B.E.2
Prager, D.E.3
-
31
-
-
18244371651
-
Acquired resiteance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W, Miller WA, Politi KA et al Acquired resiteance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2(3): e73.
-
(2005)
PLoS Med
, vol.2
, Issue.3
-
-
Pao, W.1
Miller, W.A.2
Politi, K.A.3
-
32
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
DOI 10.1056/NEJMoa044238
-
Kobayashi S, Boggon TJ, Dayram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 2005; 352(8): 786-792. (Pubitemid 40271173)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.8
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
Janne, P.A.4
Kocher, O.5
Meyerson, M.6
Johnson, B.E.7
Eck, M.J.8
Tenen, D.G.9
Halmos, B.10
-
33
-
-
72949092456
-
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
-
Zhou W, Ercan D, Chen L et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462(7276): 1070-1074.
-
(2009)
Nature
, vol.462
, Issue.7276
, pp. 1070-1074
-
-
Zhou, W.1
Ercan, D.2
Chen, L.3
-
34
-
-
34250732736
-
Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M
-
Jančaříková D, Pešek M, Benešová L et al. Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M. Anticancer Res 2007; 27(4A): 1879-1882.
-
(2007)
Anticancer Res
, vol.27
, Issue.4 A
, pp. 1879-1882
-
-
Jančaříková, D.1
Pešek, M.2
Benešová, L.3
-
35
-
-
34347208648
-
Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy
-
DOI 10.1016/j.ccr.2007.06.005, PII S1535610807001742
-
Li D, Shinamura T, Ji H et al Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007; 12(1): 81-93. (Pubitemid 47001787)
-
(2007)
Cancer Cell
, vol.12
, Issue.1
, pp. 81-93
-
-
Li, D.1
Shimamura, T.2
Ji, H.3
Chen, L.4
Haringsma, H.J.5
McNamara, K.6
Liang, M.-C.7
Perera, S.A.8
Zaghlul, S.9
Borgman, C.L.10
Kubo, S.11
Takahashi, M.12
Sun, Y.13
Chirieac, L.R.14
Padera, R.F.15
Lindeman, N.I.16
Janne, P.A.17
Thomas, R.K.18
Meyerson, M.L.19
Eck, M.J.20
Engelman, J.A.21
Shapiro, G.I.22
Wong, K.-K.23
more..
-
36
-
-
79955559582
-
Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer
-
Presented at the abstract 203
-
Besse B, Eaton KD, Soria JC et al. Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer. Presented at the 20th Annual EORTC-NCI-AACR Symposium, Geneva, Switzerland 2008, abstract 203.
-
20th Annual EORTC-NCI-AACR Symposium, Geneva, Switzerland 2008
-
-
Besse, B.1
Eaton, K.D.2
Soria, J.C.3
-
37
-
-
77951643141
-
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
-
Ercan D, Zejnullahu K, Yonesaka K et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010; 29(16): 2346-2356.
-
(2010)
Oncogene
, vol.29
, Issue.16
, pp. 2346-2356
-
-
Ercan, D.1
Zejnullahu, K.2
Yonesaka, K.3
-
38
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
DOI 10.1126/science.1141478
-
Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316(5827). 1039-1043. (Pubitemid 46799492)
-
(2007)
Science
, vol.316
, Issue.5827
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
Song, Y.4
Hyland, C.5
Joon, O.P.6
Lindeman, N.7
Gale, C.-M.8
Zhao, X.9
Christensen, J.10
Kosaka, T.11
Holmes, A.J.12
Rogers, A.M.13
Cappuzzo, F.14
Mok, T.15
Lee, C.16
Johnson, B.E.17
Cantley, L.C.18
Janne, P.A.19
-
39
-
-
34249984736
-
HER3 and mutant EGFR meet MET
-
DOI 10.1038/nm0607-675, PII NM0607675
-
Arteaga CL. HER3 and mutant EGFR meet MET Nat Med 2007; 13(6): 675-677. (Pubitemid 46889747)
-
(2007)
Nature Medicine
, vol.13
, Issue.6
, pp. 675-677
-
-
Arteaga, C.L.1
-
40
-
-
73649102105
-
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
-
Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 2010; 17(1): 77-88
-
(2010)
Cancer Cell
, vol.17
, Issue.1
, pp. 77-88
-
-
Turke, A.B.1
Zejnullahu, K.2
Wu, Y.L.3
-
41
-
-
71849120012
-
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
-
Yoshida T, Okamoto I, Okamoto W et al. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 2010; 101(1): 167-172.
-
(2010)
Cancer Sci
, vol.101
, Issue.1
, pp. 167-172
-
-
Yoshida, T.1
Okamoto, I.2
Okamoto, W.3
-
42
-
-
77958074157
-
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation
-
Okamoto W, Okamoto I, Tanaka K et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 2010; 9(10): 2785-2792.
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.10
, pp. 2785-2792
-
-
Okamoto, W.1
Okamoto, I.2
Tanaka, K.3
-
43
-
-
46749156706
-
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
-
DOI 10.1172/JC134588
-
Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118(7): 2609-2619. (Pubitemid 351949788)
-
(2008)
Journal of Clinical Investigation
, vol.118
, Issue.7
, pp. 2609-2619
-
-
Guix, M.1
Faber, A.C.2
Wang, S.E.3
Olivares, M.G.4
Song, Y.5
Qu, S.6
Rinehart, C.7
Seidel, B.8
Yee, D.9
Arteaga, C.L.10
Engelman, J.A.11
-
44
-
-
77953000554
-
EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry
-
Sholl LM, Xiao Y, Joshi V et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010; 133(6): 922-934.
-
(2010)
Am J Clin Pathol
, vol.133
, Issue.6
, pp. 922-934
-
-
Sholl, L.M.1
Xiao, Y.2
Joshi, V.3
-
45
-
-
44249125258
-
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
-
Jänne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib- resistant tumours. Lung Cancer 2008; 60 (Suppl 2): S3-S9.
-
(2008)
Lung Cancer
, vol.60
, Issue.SUPPL. 2
-
-
Jänne, P.A.1
-
46
-
-
35348984876
-
Využití laserové mikrodisekce pro přípravu komplexních vzorků z nádorové tkáně pro účely mikrogenomických analýz
-
Dziechciarková M, Berkovcová J, Trojanec R et al. Využití laserové mikrodisekce pro přípravu komplexních vzorků z nádorové tkáně pro účely mikrogenomických analýz. Klin Onkol 2007; 20: 323-329.
-
(2007)
Klin Onkol
, vol.20
, pp. 323-329
-
-
Dziechciarková, M.1
Berkovcová, J.2
Trojanec, R.3
-
47
-
-
79955565394
-
Využiti laserové mikrodisekce pro přípravu komplexních vzorků z nádorové tkáně pro účely mikrogenomických analýz
-
Dziechciarková M, Berkovcová J, Trojanec R et al. Využiti laserové mikrodisekce pro přípravu komplexních vzorků z nádorové tkáně pro účely mikrogenomických analýz. Klin Onkol 2006; 19 (Suppl): 355-360.
-
(2006)
Klin Onkol
, vol.19
, Issue.SUPPL.
, pp. 355-360
-
-
Dziechciarková, M.1
Berkovcová, J.2
Trojanec, R.3
-
48
-
-
70349307029
-
Targeted therapies in the treatment of advanced non-small-cell lung cancer: Update
-
Mendoza L. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update. Klin Onkol 2009; 22(4): 131-138.
-
(2009)
Klin Onkol
, vol.22
, Issue.4
, pp. 131-138
-
-
Mendoza, L.1
-
49
-
-
33751079351
-
Predikce účinnoti tyrozinkinázových inhibitorů EGFR1 v léčbě nemalobuněč ných plicních karcinomů
-
Berkovcová J, Hajdúch M, Dziechciarková M et al. Predikce účinnoti tyrozinkinázových inhibitorů EGFR1 v léčbě nemalobuněčných plicních karcinomů. Klin Onkol 19(3): 171-176
-
Klin Onkol
, vol.19
, Issue.3
, pp. 171-176
-
-
Berkovcová, J.1
Hajdúch, M.2
Dziechciarková, M.3
-
50
-
-
0037532742
-
Long-term trends in cancer mortality in the United States, 1930-1998
-
Wingo PA, Cardinez CJ, Landis SH et al. Long-Term Trends in Cancer Mortality in the United States, 1930-1998. Cancer 2003; 97 (Suppl 12): 3133-3275. (Pubitemid 36667543)
-
(2003)
Cancer
, vol.97
, Issue.12 SUPPL.
, pp. 3133-3275
-
-
Wingo, P.A.1
Cardinez, C.J.2
Landis, S.H.3
Greenlee, R.T.4
Ries, L.A.G.5
Anderson, R.N.6
Thun, M.J.7
-
51
-
-
75149159481
-
-
verze 7.0. Masarykova univerzita, Brno, ČR [aktualizováno 14. Iedna 2011; citováno 14. ledna 2011]. Dostupné z
-
Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice, verze 7.0. Masarykova univerzita, Brno, ČR 2007 [aktualizováno 14. Iedna 2011; citováno 14. ledna 2011]. Dostupné z. http://www.svod.cz.
-
(2007)
Epidemiologie Zhoubných Nádorů V České Republice
-
-
Dušek, L.1
Mužík, J.2
Kubásek, M.3
|